课题基金 / 基金详情

Survivor QOL/Spouse Satisfaction after Prostate Therapy

Survivor QOL/Spouse Satisfaction after Prostate Therapy
前列腺治疗后幸存者的生活质量/配偶满意度
批准号:
6623053
负责人:
MARTIN G SANDA
金额:
$58.03万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2003-12-09

项目摘要

项目成果

MARTIN G SANDA的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):背景:健康相关生活质量(HRQOL)是 这是早期前列腺癌幸存者及其配偶的关键问题。 最近的发展,包括近距离放射治疗(BT)的出现, 三维适形放射治疗(3D-ERT)的发展, 辅助激素治疗,并观察到根治性乳腺癌切除术(RP) 结果可能会有所不同的从业者,燃料需要重新评估HRQOL 在这方面的成果。BT、3D-ERT和RP后的HRQOL尚未被 用经验证的仪器表征,以检测这些中的每一种的影响, 干预措施。此外,患者或提供者决定患者HRQOL, 患者满意度和配偶满意度仍然不确定。因为 前列腺癌幸存者和专家确定,现有的HRQOL 工具缺乏同时评价BT对HRQOL影响的关键项目, ERT和RP,我们开发并验证了扩展前列腺癌指数 复合(EPIC)工具,使用一个队列,平等地代表每一个 这三个干预措施。因子分析揭示了2个新的HRQOL领域 (尿液刺激和激素)补充3个功能域 UCLA-PCI(尿失禁、肠失禁、性交)。5个HRQOL领域, EPIC显示了令人满意的内部一致性,可靠性和外部 效度1014例BT、3D-ERT或RP患者的横断面HRQOL比较 幸存者和对照组显示,每个EPIC HRQOL领域都对 受至少一种疗法的影响。EPIC HRQOL领域评分相关 与患者满意度显著相关,对基线因素敏感 例如年龄、癌症严重程度和前列腺大小。我们假设病人 和提供者特征影响近距离放射治疗后HRQOL的变化,外部 放疗或直肠切除术,这些干预措施具有不同的HRQOL 影响患者和配偶的长期满意度。拟议 观察性研究具有以下特定目的:1)评估基线 BT后长期HRQOL的决定因素,包括提供者特征, 3D-ERT或RP; 2)表征患者和配偶的基线决定因素 对干预过程和结果的满意度; 3)评估效果 HRQOL结果和满意度的治疗选择。 实验设计:一项前瞻性、观察性、多机构研究 将在5个预先存在的多学科机构进行 BT、3D-ERT和RP方面的专业知识。早期前列腺癌患者 选择接受BT、3D-ERT或RP作为主要治疗的患者将有资格。 基线人口统计学、癌症严重程度指标和提供者特征 将记录,而HRQOL将使用EPIC调查工具测量 在基线(治疗前)给药;然后在2个月、6个月和每年给药 治疗3年后。多层面SSS-10工具,管理 对幸存者及其配偶或生活伴侣的满意度, 过程和结果。主要终点将是EPIC领域的变化 从基线到治疗后2年的总评分,以及存活者 夫妻满意度和夫妻满意度。对于每个程序,HRQOL都会发生变化 随着时间的推移,每年的满意度得分将通过混合效应进行建模 模型;将确定影响变化的基线风险因素。的影响 在控制风险后,将比较每种治疗对HRQOL变化的影响 在上一步骤中确定的因素。这项前瞻性研究的结果, 观察性研究将提供基准,以指导结果预期, 以促进关于治疗的循证决策。
英文摘要
DESCRIPTION (provided by applicant): Background: Health related quality of life (HRQOL) is a pivotal concern for early stage prostate cancer survivors and their spouses. Recent developments, including the emergence of brachytherapy (BT), the development of 3-D conformal radiotherapy (3D-ERT), the increased use of adjuvant hormonal therapy, and the observation that radical prostatectomy (RP) outcomes may differ between practitioners, fuel a need to re-evaluate HRQOL outcomes in this context. HRQOL following BT, 3D-ERT, and RP have not been characterized with an instrument validated to detect effects of each of these interventions. Moreover, patient or provider determinants of patient HRQOL, patient satisfaction, and spouse satisfaction remain uncharacterized. Because prostate cancer survivors and experts determined that existing HRQOL instruments lacked key items for concurrently evaluating HRQOL effects of BT, ERT, and RP, we developed and validated the Expanded Prostate Cancer Index Composite (EPIC) instrument using a cohort that equally represented each of these 3 interventions. Factor analysis revealed 2 new HRQOL domains (urinary-irritative and hormonal) complementing the 3 function domains of UCLA-PCI (urinary-incontinence, bowel, sexual). The 5 HRQOL domains measured by EPIC showed satisfactory internal consistency, reliability, and external validity. Cross-sectional HRQOL comparison among 1014 BT, 3D-ERT, or RP survivors and controls showed that each EPIC HRQOL domain was adversely affected by at least one of the therapies. EPIC HRQOL domain scores associated significantly with patient satisfaction and were sensitive to baseline factors such as age, cancer severity, and prostate size. We hypothesize that patient and provider characteristics affect HRQOL changes after brachytherapy, external radiation, or prostatectomy, and that these interventions have different HRQOL effects, which impact long-term patient and spouse satisfaction. The proposed observational study has the following Specific Aims: 1) To assess baseline determinants, including provider characteristics, of long-term HRQOL after BT, 3D-ERT, or RP; 2) To characterize baseline determinants of patient and spouse satisfaction with intervention process and outcome; and 3) To evaluate effects of therapy choice on HRQOL outcome and satisfaction. Experimental Design: A prospective, observational, multi-institutional study will be performed at 5 institutions with pre-existing, multi-disciplinary expertise in BT, 3D-ERT, and RP. Patients with early stage prostate cancer electing to undergo BT, 3D-ERT, or RP as primary therapy will be eligible. Baseline demographics, cancer severity measures, and provider characteristics will be recorded, while HRQOL will be measured using the EPIC survey instrument administered at baseline (pre-therapy); then at 2 months, 6 months, and yearly after therapy for 3 years. The multidimensional SSS-10 instrument, administered to survivors and their spouses or life partners, will measure satisfaction with process and outcome. The principal endpoints will be changes in EPIC domain summary scores from baseline to two years after therapy, and survivor satisfaction as well as spouse satisfaction. For each procedure, HRQOL changes over time and yearly satisfaction scores will be modeled by a mixed effects model; baseline risk factors that affect change will be identified. The effects of each therapy on change in HRQOL will be compared after controlling for risk factors identified in the previous step. The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
University of Michigan O'Brien Center for Urology Research
University of Michigan O'Brien Center for Urology Research